Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

PHASE3CompletedINTERVENTIONAL
Enrollment

1,617

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

August 27, 2019

Conditions
ASCVDRisk Factor, CardiovascularElevated Cholesterol
Interventions
DRUG

Inclisiran Sodium

Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

DRUG

Placebo

Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).

Trial Locations (70)

184

Research Site 11027-006, Pretoria

1036

Research Site 11036-001, Budapest

1619

Research Site 11027-005, Johannesburg

2002

Research Site - 11380-001, Kyiv

3000

Research Site 11036-002, Hatvan

3037

Research Site - 11380-002, Kyiv

3049

Research Site - 11380-003, Kyiv

3115

Research Site - 11380-004, Kiev

Research Site - 11380-009, Kiev

4025

Research Site 11036-004, Debrecen

4103

Research Site 11049-001, Leipzig

7130

Research Site 11027-007, Kuils River

Research Site 11027-004, Somerset West

7500

Research Site 11027-001, Cape Town

7646

Research Site 11027-013, Cape Town

8800

Research Site - 11380-006, Uzhhorod

8900

Research Site 11036-003, Zalaegerszeg

9301

Research Site 11027-003, Bloemfontein

9459

Research Site 11027-011, Welkom

12567

Research Site 11049-006, Berlin

18009

Research Site - 11380-005, Cherkasy

43001

Research Site 11420-002, Chomutov

44787

Research Site 11049-002, Bochum

60313

Research Site 11049-003, Frankfurt

61444

Research Site - 11380-008, Kharkiv

68601

Research Site 11420-003, Uherské Hradiště

69120

Research Site 11049-007, Heidelberg

79060

Research Site - 11380-007, Lviv

85-079

Research Site 11048-018, Bydgoszcz

36-200

Research Site 11048-016, Brzozów

41-709

Research Site 11048-019, Ruda Śląska

85-231

Research Site 11048-011, Bydgoszcz

80-382

Research Site 11048-004, Gdansk

80-542

Research Site 11048-017, Gdansk

81-537

Research Site 11048-005, Gdynia

04-040

Research Site 11048-007, Katowice

40-648

Research Site 11048-012, Katowice

31-216

Research Site 11048-014, Krakow

31-501

Research Site 11048-003, Krakow

20-709

Research Site 11048-008, Lublin

60-702

Research Site 11048-001, Poznan

35-055

Research Site 11048-013, Rzeszów

33-100

Research Site 11048-015, Tarnów

04-628

Research Site 11048-009, Warsaw

01-192

Research Site 11048-006, Warszawice

50-381

Research Site 11048-002, Wroclaw

51-314

Research Site 11048-010, Wroclaw

B15 2SQ

Research Site - 11044-006, Edgbaston

M33 2RH

Research Site - 11044-022, Sale

M33 4BR

Research Site - 11044-023, Sale

WA14 5PF

Research Site - 11044-021, Timperley

PL14 3XA

Research Site - 11044-012, Liskeard

EX2 5DW

Research Site - 11044-009, Exeter

PL5 3JB

Research Site - 11044-019, Plymouth

PR7 7NA

Research Site - 11044-014, Chorley

L22 0LG

Research Site - 11044-004, Waterloo

M41 7WJ

Research Site - 11044-027, Davyhulme

SK10 5JH

Research Site - 11044-028, Bollington

BL9 ONJ

Research Site - 11044-026, Bury

CF15 9SS

Research Site - 11044-007, Cardiff

SK8 5LL

Research Site - 11044-024, Cheadle Hulme

S40 4AA

Research Site - 11044-010, Derby

G20 0SP

Research Site - 11044-001, Glasgow

NE46 1QJ

Research Site - 11044-008, Hexham

SK11 6JL

Research Site - 11044-020, Macclesfield

M14 6WP

Research Site - 11044-025, Manchester

M15 6SX

Research Site - 11044-005, Manchester

M20 2RN

Research Site - 11044-029, Manchester

RG2 0TG

Research Site - 11044-003, Reading

TS19 8PE

Research Site - 11044-002, Stockton

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY